{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:48:51Z","timestamp":1762660131597,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":546,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.exphem.2021.10.006","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T03:08:49Z","timestamp":1636427329000},"page":"39-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance"],"prefix":"10.1016","volume":"105","author":[{"given":"Fangbing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiushi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Gai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-5778","authenticated-orcid":false,"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2021.10.006_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-020-00964-1","article-title":"Management of acute myeloid leukemia (AML) in older patients","volume":"22","author":"Abdallah","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.exphem.2021.10.006_bib0002","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/sj.leu.2400854","article-title":"High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate","volume":"11","author":"Lauria","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.10.006_bib0003","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"Schimmer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.10.006_bib0004","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.10.006_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajh.10453","article-title":"Mcl-1 and Bcl-2\/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia","volume":"75","author":"Saxena","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2021.10.006_bib0006","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.10.006_bib0007","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2021.10.006_bib0008","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2021.10.006_bib0009","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1038\/sigtrans.2017.12","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2021.10.006_bib0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2021.10.006_bib0011","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13492","article-title":"Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML","volume":"105","author":"Hormi","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2021.10.006_bib0012","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.10.006_bib0013","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2021.10.006_bib0014","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2021.10.006_bib0015","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","article-title":"Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia","volume":"104","author":"Li","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2021.10.006_bib0016","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.10.006_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-014-0053-9","article-title":"CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells","volume":"7","author":"Qi","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2021.10.006_bib0018","doi-asserted-by":"crossref","first-page":"e76662","DOI":"10.1371\/journal.pone.0076662","article-title":"Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2021.10.006_bib0019","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-10-1707","article-title":"Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia","volume":"16","author":"Xie","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.10.006_bib0020","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2021.10.006_bib0021","doi-asserted-by":"crossref","first-page":"e79106","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2021.10.006_bib0022","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41418-018-0183-7","article-title":"BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL","volume":"26","author":"Greaves","year":"2019","journal-title":"Cell Death Differ"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X21004240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X21004240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:36:35Z","timestamp":1759566995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X21004240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":22,"alternative-id":["S0301472X21004240"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2021.10.006","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2021.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}